About Biosimilars Council
Our Mission
The Biosimilars Council works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, providing billions in savings to patients and the health care system. Our members include biosimilar manufacturers and stakeholders working to promote biosimilar products in the U.S. market.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org.
“Biosimilars hold the key to ensuring affordable access to biologic-alternatives medicines for all consumers. We exist to educate, advocate, and promote the development of these products.”
– Biosimilars Council Executive Director,
Craig Burton
Become a Member
Learn why the Biosimilars Council is the “go-to” source for information about policy, regulatory or legislative issues in the biosimilars industry. When your company invests in Biosimilars Council membership through the Association for Accessible Medicines, we amplify your voice and advocate for your interests.
Our Team
Craig Burton | Executive Director, Biosimilars Council
Senior Vice President, Policy & Strategic Alliances, Association for Accessible Medicines (AAM)
Craig Burton is the Senior Vice President of Policy and Strategic Alliances for the Association for Accessible Medicines and the Executive Director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups.
With more than 20 years of Federal health policy experience, Craig has served in key roles at the center of a range of pressing health care debates. Prior to joining AAM in 2017, Craig was at Avalere Health, where he helped clients anticipate and plan for the impact of change stemming from legislative, regulatory, or other market dynamics. Craig also established and directed the health policy and government relations efforts for two biopharmaceutical companies.
Craig served as Deputy Assistant Secretary for Legislation in the U.S. Department of Health and Human Services. In this role, he advised the Secretary, senior Department leaders and White House officials on legislative strategy to achieve key priorities. Craig also served in the Senate, where he was Health Policy Advisor to Senate Majority Leader Bill Frist, M.D., and as professional staff on the U.S. Senate Committee on Health, Education, Labor and Pensions.
Alisha Sud
Director, Policy, Association for Accessible Medicines (AAM)
Alisha Sud is Director of Policy at the Association for Accessible Medicines. Alisha is responsible for collaborating with leadership to identify and respond to key policy issues affecting AAM and Biosimilars Council members. She also manages research initiatives, public comments, policy papers, and other materials that advance the strategic goals and mission of AAM and the Biosimilars Council.
Prior to joining AAM, Alisha was Associate Director of FasterCures, a center of the Milken Institute focused on creating a patient-centered system that accelerates science research, dismantles barriers to access, and connects patients with treatments. Alisha previously worked at global strategic advisory and commercial diplomacy firm Albright Stonebridge Group.
Alisha has extensive experience working with public and private stakeholders to advance global and domestic health policy initiatives. Alisha received her Bachelor of Arts from the University of Vermont with a degree in International Development and a certificate in International Studies from the Johns Hopkins University School of Advanced International Studies. Alisha is currently a Master of Public Health candidate at the Bloomberg School of Public Health.